M-TEER Benefits in Secondary Mitral Regurgitation: Consistent Clinical and Quality-of-Life Improvements Regardless of Baseline Health Status
Posted inCardiology news

M-TEER Benefits in Secondary Mitral Regurgitation: Consistent Clinical and Quality-of-Life Improvements Regardless of Baseline Health Status

The RESHAPE-HF2 trial reveals that mitral transcatheter edge-to-edge repair (M-TEER) significantly reduces cardiovascular risks and enhances health status across all baseline patient conditions, reinforcing its role as a key intervention for symptomatic heart failure and secondary mitral regurgitation.
The Price of Time: 20-Year Study Reveals Pre-Hospital Delay as a Critical Driver of STEMI Mortality
Posted inCardiology Emergency Medicine news

The Price of Time: 20-Year Study Reveals Pre-Hospital Delay as a Critical Driver of STEMI Mortality

A 20-year analysis of 89,155 patients from the SWEDEHEART registry confirms that pre-hospital delay independently predicts short- and long-term mortality. Despite advances in reperfusion, women, elderly patients, and those with diabetes consistently experience significantly longer delays, highlighting a critical need for targeted public health interventions.
Tại sao cửa sổ Parasternal có thể trở thành tiêu chuẩn vàng mới cho việc định lượng hở van động mạch chủ
Posted innews

Tại sao cửa sổ Parasternal có thể trở thành tiêu chuẩn vàng mới cho việc định lượng hở van động mạch chủ

Một nghiên cứu đột phá cho thấy việc đo hội tụ dòng chảy từ cửa sổ trục dài parasternal vượt trội hơn đáng kể so với phương pháp PISA đỉnh trong khả năng thực hiện và đạt độ chính xác tương đương với MRI tim trong việc đánh giá mức độ nghiêm trọng của hở van động mạch chủ.
Oral Magnesium Reduces Risk of Death and Hospitalization in Heart Failure Patients with Hypomagnesemia
Posted inCardiology Internal Medicine news

Oral Magnesium Reduces Risk of Death and Hospitalization in Heart Failure Patients with Hypomagnesemia

A large-scale study of US veterans demonstrates that oral magnesium therapy significantly improves outcomes in heart failure patients with hypomagnesemia, especially those with levels below 1.3 mg/dL. Conversely, supplementation in normomagnesemic patients may increase risks, highlighting the necessity of baseline-guided clinical intervention.